In its Q3 filing with the SEC, Nichols & Pratt Advisers LLP MA reported a 1.8% increase in its position in Novo Nordisk, acquiring an additional 8,935 shares to bring its total holding to 500,991 shares. This stake represents 1.8% of the firm’s overall portfolio and stands as its 22nd largest position, with the holdings valued at $27.8 million. Across the broader institutional landscape, hedge funds and other large investors collectively own 11.54% of Novo Nordisk, with notable activity including True Wealth Design LLC boosting its holding by 209.8% and NewSquare Capital LLC increasing its position by 174.1% during the same period.

Novo Nordisk unveiled headline results from the REIMAGINE 2 trial, a 68-week, 2,728-patient study comparing once-weekly CagriSema (cagrilintide/semaglutide) to semaglutide alone at matched doses. Patients starting from a mean HbA1c of 8.2% achieved a 1.91-point reduction on CagriSema 2.4 mg/2.4 mg versus a 1.76-point drop with semaglutide 2.4 mg. From a mean baseline weight of 101 kg, CagriSema delivered 14.2% body-weight loss compared with 10.2% for semaglutide. No weight-loss plateau was observed at week 68, and 43% of CagriSema patients attained at least 15% weight loss. The combination was well tolerated, with predominantly mild to moderate gastrointestinal events that diminished over time. Based on these results, Novo Nordisk filed for U.S. regulatory approval in December 2025 and plans further discussions on the type 2 diabetes indication.